HARMONY BIOSCIENCES HOLDINGS (HRMY)
US4131971040 - Common Stock
HRMY gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. HRMY scores excellent points on both the profitability and health parts. This is a solid base for a good stock. HRMY is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make HRMY suitable for value and quality investing!
1. Profitability
1.1 Basic Checks
HRMY had positive earnings in the past year.
HRMY had a positive operating cash flow in the past year.
In multiple years HRMY reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: HRMY reported negative operating cash flow in multiple years.
1.2 Ratios
HRMY has a Return On Assets of 13.21%. This is amongst the best in the industry. HRMY outperforms 96.35% of its industry peers.
Looking at the Return On Equity, with a value of 20.55%, HRMY belongs to the top of the industry, outperforming 92.71% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 18.64%, HRMY belongs to the top of the industry, outperforming 94.27% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for HRMY is significantly below the industry average of 42.22%.
The last Return On Invested Capital (18.64%) for HRMY is above the 3 year average (18.06%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.21% | ||
| ROE | 20.55% | ||
| ROIC | 18.64% |
ROA(3y)16.93%
ROA(5y)-27.92%
ROE(3y)30.4%
ROE(5y)N/A
ROIC(3y)18.06%
ROIC(5y)N/A
1.3 Margins
HRMY has a Profit Margin of 17.98%. This is amongst the best in the industry. HRMY outperforms 91.67% of its industry peers.
HRMY has a Operating Margin of 28.21%. This is amongst the best in the industry. HRMY outperforms 93.23% of its industry peers.
In the last couple of years the Operating Margin of HRMY has grown nicely.
The Gross Margin of HRMY (78.65%) is better than 83.85% of its industry peers.
HRMY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.21% | ||
| PM (TTM) | 17.98% | ||
| GM | 78.65% |
OM growth 3Y46.09%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.43%
GM growth 5YN/A
2. Health
2.1 Basic Checks
HRMY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
HRMY has less shares outstanding than it did 1 year ago.
The number of shares outstanding for HRMY has been reduced compared to 5 years ago.
The debt/assets ratio for HRMY has been reduced compared to a year ago.
2.2 Solvency
HRMY has an Altman-Z score of 5.20. This indicates that HRMY is financially healthy and has little risk of bankruptcy at the moment.
HRMY has a Altman-Z score of 5.20. This is amongst the best in the industry. HRMY outperforms 80.73% of its industry peers.
HRMY has a debt to FCF ratio of 0.83. This is a very positive value and a sign of high solvency as it would only need 0.83 years to pay back of all of its debts.
HRMY's Debt to FCF ratio of 0.83 is amongst the best of the industry. HRMY outperforms 96.88% of its industry peers.
A Debt/Equity ratio of 0.28 indicates that HRMY is not too dependend on debt financing.
HRMY's Debt to Equity ratio of 0.28 is in line compared to the rest of the industry. HRMY outperforms 41.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 0.83 | ||
| Altman-Z | 5.2 |
ROIC/WACC2.08
WACC8.95%
2.3 Liquidity
HRMY has a Current Ratio of 3.24. This indicates that HRMY is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.24, HRMY is in line with its industry, outperforming 52.08% of the companies in the same industry.
A Quick Ratio of 3.20 indicates that HRMY has no problem at all paying its short term obligations.
HRMY has a Quick ratio of 3.20. This is comparable to the rest of the industry: HRMY outperforms 55.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.24 | ||
| Quick Ratio | 3.2 |
3. Growth
3.1 Past
HRMY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -23.55%.
HRMY shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.83%.
The Revenue has been growing by 53.89% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-23.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.33%
Revenue 1Y (TTM)25.83%
Revenue growth 3Y53.89%
Revenue growth 5YN/A
Sales Q2Q%16.08%
3.2 Future
Based on estimates for the next years, HRMY will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.53% on average per year.
Based on estimates for the next years, HRMY will show a very strong growth in Revenue. The Revenue will grow by 25.22% on average per year.
EPS Next Y-3.11%
EPS Next 2Y16.88%
EPS Next 3Y24.77%
EPS Next 5Y18.53%
Revenue Next Year22.05%
Revenue Next 2Y20.03%
Revenue Next 3Y19.88%
Revenue Next 5Y25.22%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
HRMY is valuated correctly with a Price/Earnings ratio of 15.55.
Based on the Price/Earnings ratio, HRMY is valued cheaply inside the industry as 86.46% of the companies are valued more expensively.
HRMY's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.65.
With a Price/Forward Earnings ratio of 9.92, the valuation of HRMY can be described as very reasonable.
Based on the Price/Forward Earnings ratio, HRMY is valued cheaply inside the industry as 88.02% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of HRMY to the average of the S&P500 Index (23.56), we can say HRMY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.55 | ||
| Fwd PE | 9.92 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HRMY indicates a rather cheap valuation: HRMY is cheaper than 90.10% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of HRMY indicates a rather cheap valuation: HRMY is cheaper than 93.23% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.5 | ||
| EV/EBITDA | 7.48 |
4.3 Compensation for Growth
The decent profitability rating of HRMY may justify a higher PE ratio.
HRMY's earnings are expected to grow with 24.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.88%
EPS Next 3Y24.77%
5. Dividend
5.1 Amount
No dividends for HRMY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HARMONY BIOSCIENCES HOLDINGS
NASDAQ:HRMY (11/21/2024, 12:02:26 PM)
32.805
+0.02 (+0.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.87B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.55 | ||
| Fwd PE | 9.92 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.21% | ||
| ROE | 20.55% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 28.21% | ||
| PM (TTM) | 17.98% | ||
| GM | 78.65% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.24 | ||
| Quick Ratio | 3.2 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-23.55%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-3.11%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)25.83%
Revenue growth 3Y53.89%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y